Health Care & Life Sciences » Biotechnology | Stemline Therapeutics Inc.

Stemline Therapeutics Inc. | Ownership

Companies that own Stemline Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Consonance Capital Management LP
2,747,198
8.86%
140,600
2.5%
06/30/2018
Polar Capital LLP
1,912,605
6.18%
1,539,320
0.07%
06/30/2018
BlackRock Fund Advisors
1,665,711
5.38%
214,098
0%
06/30/2018
Fidelity Management & Research Co.
1,603,170
5.18%
-389,871
0%
07/31/2018
Lyon Street Capital LLC
1,471,518
4.75%
230,225
7.89%
06/30/2018
The Vanguard Group, Inc.
1,205,372
3.89%
124,705
0%
06/30/2018
Adage Capital Management LP
1,160,014
3.75%
-632,043
0.04%
06/30/2018
Eventide Asset Management LLC
1,086,400
3.51%
0
0.71%
06/30/2018
SSgA Funds Management, Inc.
1,044,477
3.37%
149,045
0%
06/30/2018
Citadel Advisors LLC
825,074
2.66%
240,201
0.02%
06/30/2018

About Stemline Therapeutics

View Profile
Address
750 Lexington Avenue
New York New York 10022
United States
Employees -
Website http://www.stemline.com
Updated 07/08/2019
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.